We are live on ! Find out more
ROSG

Rosetta Genomics Ltd.
ROSG

Delisted

ROSG was delisted on the 21st of May, 2018.

9 hedge funds and large institutions have $315K invested in Rosetta Genomics Ltd. in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

18% less funds holding

Funds holding: 119 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

54% less capital invested

Capital invested by funds: $689K → $315K (-$374K)

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.22%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
3
Reduced
3
Closed
4
Calls
Puts
Net Calls
Net Calls Change

ROSG Hedge Fund Activity: Q1 2017 in Review

9 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q1 2017, worth a combined $315K — down 54% from $689K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ROSG and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was Morgan Stanley, adding an estimated $132K. The largest seller was Sabby Management, exiting entirely with an estimated $248K sold.

  • 9 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q1 2017, down from 11 in Q4 2016.
  • Funds reported $315K of Rosetta Genomics Ltd. stock for Q1 2017, down 54% quarter-over-quarter.
  • 2 funds opened new Rosetta Genomics Ltd. positions in Q1 2017 and 4 closed out, a net change of -2 holders.
  • The largest Rosetta Genomics Ltd. buyer in Q1 2017 was Morgan Stanley, an estimated $132K added.
  • The largest Rosetta Genomics Ltd. seller in Q1 2017 was Sabby Management, an estimated $248K sold.

Based on aggregated 13F filings for Q1 2017.